Unlock instant, AI-driven research and patent intelligence for your innovation.

Whole human anti-human interleukin-17A antibody and application thereof

A human interleukin, fully human-sourced technology, applied in the field of biomedicine, can solve problems such as inability to effectively cause CDC

Active Publication Date: 2019-01-15
BEIJING WEIFENG YIMIN TECH
View PDF17 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In therapeutic applications, fully human antibodies can overcome many shortcomings of mouse monoclonal antibodies in clinical applications: such as inducing anti-mouse antibody (HAMA) reactions in the human body, inability to effectively induce CDC and ADCC, etc.
However, the relatively limited affinity of this antibody can be a limitation in clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Whole human anti-human interleukin-17A antibody and application thereof
  • Whole human anti-human interleukin-17A antibody and application thereof
  • Whole human anti-human interleukin-17A antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Example 1 Affinity Maturation of Antibodies

[0077] 1.1 Preparation of yeast electrotransformation competent

[0078] 1) From a fresh YPD plate, pick EBY100 yeast (Invitrogen TM ) monoclonal in 5mL YPD medium. Incubate overnight at 30°C.

[0079] 2) Inoculate the overnight culture into 50 mL of YPD medium, the initial concentration is OD600=0.1, and cultivate at 30°C until OD600=1.3-1.5, and the process takes about 6 hours.

[0080] 3) When the cells are cultured to OD600=1.3-1.5, add 500 μL of Tris-DTT buffer to the culture medium. Shake in a shaker at 30°C for 15 minutes.

[0081] 4) Centrifuge the culture at 2500 g for 3 minutes at 4°C, and gently resuspend the culture with 25 mL of ice-cold 1 M sorbitol to wash the cell pellet. Centrifuge, wash the cell pellet by gently resuspending in 1 mL of ice-cold 1M sorbitol, and centrifuge.

[0082] 5) Resuspend the cell pellet with ice-cold double-distilled water to a final volume of 300 μL, and place it on ice for la...

Embodiment 2

[0140] Example 2 Full-length antibody protein expression and purification

[0141] 1) 293FT suspension cells

[0142] Need to maintain 4×10 5 to 3×10 6 Cells / mL concentration range, usually 25mL cultured in a 125mL Erlenmeyer flask, shaker speed 120rpm, 37°C, 8% CO 2 .

[0143] 2) 24 hours before transfection cells, according to 1×10 6 cells / mL and cultured overnight, the next day the cell concentration should reach 2×10 6 cells / mL.

[0144] 3) On the day of transfection, count the cells and resuspend the cells by centrifugation to make the concentration 2.5-3.0×10 6 cells / mL.

[0145] 4) Transfer 10 mL of resuspended cells to a new 125 mL Erlenmeyer culture flask, confirm the cell concentration again, and place the cells in a cell culture incubator for culture.

[0146] 5) The gene fragments of the light chain and heavy chain of the antibody are digested by Xho1 and BamH1, and T4 enzyme is connected to the PTT5 expression vector. After the sequencing is correct, the ...

Embodiment 3

[0153] Example 3 Antibody neutralization experiment in vitro

[0154] IL-17A can induce and stimulate HT1080 (ATCC) to produce cytokine IL-6. In this experiment, the neutralizing activity of anti-IL-17A antibody was detected by IL-17A-induced HT1080 cells to produce IL-6 activity.

[0155] 1) Human fibrosarcoma cell line (HT1080) was trypsinized in a 96-well plate. Cells were counted so that there were approximately 9000 cells in each well, and cultured overnight in MEM medium containing 10% fetal bovine serum.

[0156] 2) Dilute the recombinant protein IL-17A (recombinant IL-17A antigen from PeproTech, Cat. No.: #200-17) with sterile PBS to 10 nM.

[0157] 3) The purified recombinant antibodies 9NT.NS and 9NT (Example 1) were serially diluted with sterile PBS, respectively: 1350nM, 337.5nM, 84.38nM, 21.09nM, 5.27nM, 1.32nM, 0.33nM, 0.08nM, 0.02nM And ten gradients of 0.01nM, mixed with 10nM recombinant IL-17A protein, removed HT1080 cell culture supernatant, added antibody...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a whole human anti-human interleukin-17A (IL-17A) antibody. The antibody comprises a heavy chain variable region and / or a light chain variable region. The heavy chain variableregion is a): the heavy chain variable region with an amino acid sequence shown as SEQ ID NO.1 and an encoding nucleotide sequence preferably shown as SEQ ID NO.8, or b): the heavy chain variable region obtained by changing a human heavy chain framework region in a); and the light chain variable region is a): the light chain variable region with an amino acid sequence shown as SEQ ID NO.2 and an encoding nucleotide sequence preferably shown as SEQ ID NO.9, or b): the light chain variable region obtained by changing a human light chain framework region in a). The brand new human antibody molecule of IL-17A obtained by the invention has the related biological activity of inhibiting IL-17A, and can treat IL-17A related diseases.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a fully human anti-human interleukin-17A antibody and its application. Background technique [0002] Human interleukin-17 (hIL-17) was isolated from an activated T-cell hybridoma in 1993 and was originally called cytotoxic T-cell antigen 8 (CTLA8) when it was discovered in rodents. It is currently known that IL-17, namely IL-17A, is mainly secreted by Th-17 cells, and there are six members (IL-17A-F) in the IL-17 family, which are composed of 150-180 amino acids, usually in two exist in the form of aggregates. IL-17A can induce a variety of cells (including fibroblasts, endothelial cells, epithelial cells, and macrophages) to produce other cytokines such as IL-6, G-CSF, GM-CSF, IL-1β, TGF-β, TNF-α; chemokines such as IL-8, GRO-α, and monocyte chemoattractant-1 (MCP-1); and prostaglandin PGE2. IL-17 induces an increase in the chemokines IL-8, GRO-α, and MCP-1, leading to the recruitm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/24C12N15/13A61K39/395A61P35/00A61P37/00A61P29/00A61P19/02A61P11/00A61P1/16A61P17/06
CPCA61K2039/505C07K16/244
Inventor 胡卓伟崔冰孙巍
Owner BEIJING WEIFENG YIMIN TECH